Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity

Tu-Xiong Huang,1,2 Xiang-Yu Tan,1 Hui-Si Huang,1 Yu-Ting Li,1 Bei-Lei Liu,3 Kai-Sheng Liu,2 Xinchun Chen,1 Zhe Chen,4 Xin-Yuan Guan,3 Chang Zou,2 Li Fu1

ABSTRACT

Objective Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME). Cancer-associated fibroblasts (CAFs) are a key component of the TME and negatively regulate antitumour T-cell response. Here, we aimed to uncover the mechanism underlying CAFs-mediated tumour immune evasion and to develop novel therapeutic strategies targeting CAFs for enhancing ICI efficacy in oesophageal squamous cell carcinoma (OSCC) and colorectal cancer (CRC).

Design Anti-WNT2 monoclonal antibody (mAb) was used to treat immunocompetent C57BL/6 mice bearing subcutaneously grafted mEC25 or CMT93 alone or combined with anti-programmed cell death protein 1 (PD-1), and the antitumour efficiency and immune response were assessed. CAFs-induced suppression of dendritic cell (DC)-differentiation and DC-mediated antitumour immunity were analysed by interfering with CAFs-derived WNT2, either by anti-WNT2 mAb or with short hairpin RNA-mediated knockdown. The molecular mechanism underlying CAFs-induced DC suppression was further explored by RNA-sequencing and western blot analyses.

Results A negative correlation between WNT2+ CAFs and active CD8+ T cells was detected in primary OSCC tumours. Anti-WNT2 mAb significantly restored antitumour T-cell responses within tumours and enhanced the efficacy of anti-PD-1 by increasing active DC in both mouse OSCC and CRC syngeneic tumour models. Directly interfering with CAFs-derived WNT2 restored DC differentiation and DC-mediated antitumour T-cell responses. Mechanistic analyses further demonstrated that CAFs-secreted WNT2 suppresses the DC-mediated antitumour T-cell response via the SOCS3/p-JAK2/p-STAT3 signalling cascades.

Conclusions CAFs could suppress antitumour immunity through WNT2 secretion. Targeting WNT2 might enhance the ICI efficacy and represent a new anticancer immunotherapy.

INTRODUCTION

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have shown encouraging results since they were approved in 2014 for treating various solid tumours and haematological malignancies.1 2 Nevertheless, many patients with solid malignancies do not respond to PD-1/PD-L1 checkpoint inhibitor treatment.3 4 The hindrance to achieving long-lasting therapeutic responses in solid tumours is, in part, mediated by the dynamic nature of these tumours and their complex microenvironment.5 Cancer-associated fibroblasts (CAFs) are the...
most abundant stromal cells in the tumour microenvironment (TME) and are thought to suppress antitumour immunity in a variety of solid tumours. However, the mechanisms by which CAFs regulate antitumour immune responses in solid tumours remain unclear.

Our previous study identified FGFR2 as a specific marker of pro-tumorigenic CAFs in oesophageal squamous cell carcinoma (OSCC). FGFR2+ CAFs secrete WNT2 and thus activate the Wnt/β-catenin signalling pathway to promote the malignant progression of OSCC. WNT2 is a glycoprotein ligand secreted by the Wnt signalling pathway; it can initiate intracellular signalling and participates in different processes involved in the regulation of development. WNT2 also promotes the malignant progression of other solid tumours, including colorectal cancer (CRC), gastric cancer (GC) and breast cancer (BC). The expression pattern of WNT2 varies among different cancers. In OSCC and CRC, WNT2 is mainly expressed by CAFs rather than tumour cells, but is expressed by both CAFs and tumour cells in BC and GC. WNT proteins also play an important role in the development of effector T cells, activation of regulatory T cells (Tregs), and dendritic cell (DC) differentiation and maturation. It has been reported that the overexpression of Wnt5a can suppress the differentiation of plasma-like DCs and classical DCs through non-canonical Wnt signalling pathways. The canonical Wnt/β-catenin pathway in DCs is also involved in the regulation of DC differentiation and migration. Recent studies have shown that endogenous Wnt5a or β-catenin in melanoma cells can regulate immune evasion by tumour cells via influencing the tumour infiltration or biological functions of DCs. However, to the best of our knowledge, specific targeting of WNT5A and its downstream effectors for immunotherapy has not been reported yet.

CAFs-derived WNT2 is commonly expressed in GI cancers but its role in the regulation of antitumour immunity is still largely unknown. To date, most studies have focused on the development of combination immunotherapies by blocking different immune checkpoints of immune cells to enhance the efficacy of PD-L1/PD-1 blockade. New strategies by targeting CAFs-induced immunosuppressive signalling may provide an alternative for effective combination immunotherapies in solid tumours. In this study, we sought to investigate the role of CAFs-secreted WNT2 in regulating antitumour immunity and explore a new way to develop more efficient immunotherapies for patients with GI cancer with high expression of WNT2.

MATERIALS AND METHODS
Mice and in vivo treatments
Four to six-week-old female C57BL/6 mice were purchased from Charles River Laboratories (Beijing, China) and maintained under specific pathogen-free conditions. All animal procedures were performed in accordance with guidelines approved by the Institutional Animal Care and Use Committee at Shenzhen University Health and Science Center. mEC25 cells (4 × 10⁶ cells/mouse) or mCAFs, mCAF-shWNT2 (1.3 × 10⁶ cells/mouse) or mCAF-shNTC (1.3 × 10⁶ cells/mouse) were subcutaneously injected into the right flanks of the mice. The tumour volume was calculated using the formula: Volume = π×length×width×height/6.

In vivo tumour growth assay
mEC25 cells (4 × 10⁶ cells/mouse), combined with mCAF-shWNT2 (1.3 × 10⁶ cells/mouse) or mCAF-shNTC (1.3 × 10⁶ cells/mouse) cells were subcutaneously injected into the right flanks of the mice. The tumour volume was calculated using the formula: Volume = π×length×width×height/6.

Flow cytometry analysis
For the in vitro DC differentiation analysis, mouse bone marrow DCs were generated, as previously described. Briefly, bone marrow cells of C57BL/6 mice were cultured in RPMI 1640 medium containing 10% FBS with granulocyte/macrophage colony-stimulating factor (GM-CSF) (10 ng/mL)+interleukin (IL)-4 (10 ng/mL) for 7 days to induce the cells to differentiate into DCs. The culture medium (CM) from wild-type (WT) mCAFs, mCAF-shNTC or mCAF-shWNT2 was used to treat the cells during DC induction. In some experiments, WT CAF.CM was preincubated with control IgG (MOPC-21; 100 µg/mL) or anti-WNT2 (3C4; 100 µg/mL) before DC induction. The DCs were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD11c (HL3; BD Pharmingen) and/or allophycocyanin (APC)-conjugated anti-IDO (mIDO-48; eBioscience) or anti-IL-10 (JES5-16E3; Biologend), followed by flow cytometry analysis using the CytoFLEX system and Kaluza software (Beckman Coulter). To evaluate the activities of DCs after being cultured for 7 days, as described earlier, DCs were stimulated with lipopolysaccharide (LPS) (200 ng/mL; 24 hours) followed by counter-staining with FITC-conjugated anti-CD11c (HL3) and phycoerythrin (PE)-conjugated anti-TNFα (MP6-XT22; eBioscience), anti-IL12 (C17.8; ebioscience), anti-CD80 (16-10A1; eBioscience) or anti-CD86 (mGL1; eBioscience). DCs were also stimulated with mEC25 cell lysate (1:1; 12 hours), followed by coincubation with CD8+ T cells for 5 days. The co-cultured cells were then stained with FITC-conjugated anti-CD8 (53-6-7; BD Biosciences) and APC-conjugated anti-interferon (IFN)-γ antibody (XM1G1.2; ebioscience). For the analysis of mouse tumour-derived DCs or T cells, tumour tissues were cut into small pieces, digested with 1 mg/mL collagenase IV (Sigma), and homogenised through a 100 µm mesh filter. After washing, the isolated single cells were blocked with anti-CD16/32 (93; ebioscience), followed by staining with antibodies against CD11c+TNFα, CD11c+IL12, CD11c+CD80, CD11c+CD86 or CD8+IFN-γ. For the analysis of mouse splenic T cells, the spleen was cut into small pieces and homogenised through a 100 µm mesh filter. After washing, the cell pellet was resuspended in 40% Percoll (Sigma) and the lymphocytes were isolated according to the manufacturer’s instructions. Splenic lymphocytes were blocked with anti-CD16/CD32 and counterstained with anti-CD8 and anti-IFN-γ, followed by flow cytometry analysis using the CytoFLEX system and Kaluza software (Beckman Coulter).

Additional methodology is provided as online supplemental information.

RESULTS
WNT2+ CAFs negatively correlate with effector T cells in OSCC tumours
We first investigated whether there was a correlation between WNT2+ CAFs and effector T cells within the TME. Our previous studies showed that FGFR2+ CAFs could provide a suitable microenvironment for tumour development through WNT2 secretion. Thus, WNT2+FGFR2+ CAFs were considered to be pro-tumourigenic CAFs, and their regulation of antitumour immunity was investigated in the present

Huang T-X, et al. Gut 2022;71:333–344. doi:10.1136/gutjnl-2020-322924

Gut: first published as 10.1136/gutjnl-2020-322924 on 10 March 2021; downloaded from http://gut.bmj.com on September 16, 2023 by guest. Protected by copyright.
Anti-WNT2 monoclonal antibody treatment effectively enhances antitumour immunity in OSCC and CRC

To evaluate the potential of a WNT2\textsuperscript{+} CAF-targeting strategy for enhancing antitumour responses, an anti-WNT2 monoclonal antibody (designated anti-WNT2) recently developed in our group was used alone or in combination with anti-PD-1 antibody to study its antitumour effects in syngeneic mouse OSCC and CRC models. The anti-WNT2 antibody used in this study was highly specific. It did not recognise other human WNT proteins (eg, WNT2B, WNT3A, WNT5A, WNT5B, WNT7B and WNT11), which have more than 40% homology with WNT2 (online supplemental figure 1A), but it was able to recognise both human WNT2 (hWNT2) (online supplemental figure 1A) and mouse Wnt2 (online supplemental figure 1B). Mice bearing syngeneic mEC25 tumours (figure 2A) or CMT93 tumours (online supplemental figure 2A) were treated with anti-WNT2 (200 μg/mouse) or/and anti-PD-1 (10 mg/kg/mouse) intraperitoneally every 3 days for five times. Anti-WNT2 treatment significantly suppressed the tumour growth in both OSCC (figure 2B,C) and CRC (online supplemental figure 2B,C) models. A combination of anti-WNT2 and anti-PD-1 produced more effective inhibition than anti-WNT2 or anti-PD-1 when they were used individually.

Antitumour T-cell responses were also measured in freshly resected tumours by flow cytometry. The ratio of IFN-γ CD8\textsuperscript{+} T cells/CD8\textsuperscript{+} T cells in mEC25 tumours (figure 2D) were enhanced by anti-WNT2 or anti-PD-1 treatment, compared with these values in the control. Combination treatment with anti-WNT2 and anti-PD-1 induced more activated CD8\textsuperscript{+} T cells in tumours than individual treatment with anti-WNT2 or anti-PD-1. The enhanced T-cell responses within tumours induced by anti-WNT2 or/and anti-PD-1 treatment are consistent with their growth-suppressing effects. Anti-WNT2 treatment also effectively improved the tumour-killing activity of CD8\textsuperscript{+} T cells in spleens obtained from mEC25 tumour-bearing mice (figure 2E), suggesting that anti-WNT2 may improve the initiation of adoptive antitumour immunity. DCs always play a critical role in initiation of tumour-killing T-cell responses\textsuperscript{21}. To determine whether anti-WNT2 treatment has an impact on the immune-stimulating activity of DCs, the percentage of DCs and their maturation in mEC25 tumours were examined. The percentage of CD11c\textsuperscript{+} DCs (figure 2F) or of CD103\textsuperscript{+} DCs (figure 2G) was significantly enhanced in the anti-WNT2-treated tumours compared with the percentage in the control IgG-treated tumours. Additionally, the percentage of matured DCs (CD80\textsuperscript{+}CD11c\textsuperscript{+} DCs and CD86\textsuperscript{+}CD11c\textsuperscript{+} DCs) in tumours were enhanced by anti-WNT2 treatment (figure 2H,I). Similarly, anti-WNT2 treatment also enhanced antitumour T-cell responses (online supplemental figure 2D,E) and activated DCs (online supplemental figure 2F-I) in syngeneic mouse CRC model. Notably, although anti-PD-1 enhanced more activated CD8\textsuperscript{+} T cells than anti-WNT2 in CMT93 tumours (p=0.0481; online supplemental figure 2D), it's improvement of systemic antitumour immunity in CMT93 tumour-bearing mice is significantly lower than that of anti-WNT2 (p=0.0012; online supplemental figure 2E), suggesting that anti-WNT2 may have advantages in improving initiation of adaptive antitumour immunity. These findings suggested that combination immunotherapy with anti-WNT2 and anti-PD-1 not only enhanced the systemic antitumour T-cell response but also restored the tumour-killing activity of tumour-derived CD8\textsuperscript{+} T cells, which had been suppressed by PD-L1/PD-1 signalling within the TME. Notably, anti-WNT2 treatment showed its safety in mouse tumour model since anti-WNT2 preferred to bind to tumour area rather than normal tissues including heart, liver, spleen, lung and kidney (online supplemental figure 3A,B). Moreover, no significant histological changes were detected in the above normal vital organs by anti-WNT2 treatment (online supplemental figure 3C).

CAFs-secreted WNT2 suppresses the differentiation and immune-stimulating activities of DCs in vitro

To further explore the role of WNT2 in regulating DC-mediated antitumour T-cell responses, we investigated the ability of recombinant WNT2 to suppress DC differentiation and activation by flow cytometry analyses based on the gating strategy shown in online supplemental figure 4. Compared with the control results, recombinant mouse-Wnt2 protein (mWnt2) could effectively suppress the differentiation of mouse CD11c\textsuperscript{+} DCs (online supplemental figure 5A) and CD103\textsuperscript{+} DCs (online supplemental figure 5B) in vitro. Treatment with mWnt2 also inhibited the activated phenotypes (TNFα—CD11c\textsuperscript{+} DCs and IL12—CD11c\textsuperscript{+} DCs; online supplemental figure 5C,D) and the matured phenotypes (CD80—CD11c\textsuperscript{+} DCs and CD86—CD11c\textsuperscript{+} DCs; online supplemental figure 5E,F) of DCs on stimulation with LPS. WNT2 is therefore able to suppress DC differentiation and their activated phenotypes. Importantly, mWnt2 treatment suppressed the activity of CD11c\textsuperscript{+} DCs for priming CD8\textsuperscript{+} T cells when pulsed with tumour antigens (online supplemental figure 5G). Consistently, ELISA results showed that mWnt2 treatment could inhibit the secretion of TNFα and IL12 by DCs on LPS stimulation (online supplemental figure 5H1) and the secretion of IFN-γ by CD8\textsuperscript{+} T cells which were primed by tumour antigen-loaded DCs (online supplemental figure 5J). Blockade with anti-WNT2 IgG or anti-WNT2 Fab significantly attenuated all immunosuppressive effects induced by the mWnt2 protein in vitro (online supplemental figure 5). Furthermore, we investigated whether hWNT2 protein possesses similar activity for suppressing DC function compared with that of mWnt2. Recombinant hWNT2 also suppressed the differentiation of DCs (online supplemental...
Figure 1  Correlation between WNT2+ cancer-associated fibroblasts (CAFs) and T-cell immune-stimulating activities in patients with oesophageal squamous cell carcinoma (OSCC). (A) Positive correlation between the density of WNT2+ CAFs and the ratio of Tregs/CD4+ T cells in OSCC tissue sections (n=47), expressed using Pearson’s correlation coefficient. The solid line shows the linear regression; dotted lines indicate the 95% CIs. (B) Negative correlation between the density of WNT2+ CAFs and the ratio of interferon (IFN)-γ+ CD8+ T cells/CD8+ T cells in OSCC tissue sections (n=47). (C) Representative immunofluorescence (IF) images of WNT2+ CAFs, Tregs and effector CD8+ T cells (upper) and their matched H&E images (lower) between low-WNT2 and high-WNT2+ cases. Low-WNT2+: <37 WNT2+FGFR2+ CAFs in 1 mm³ tumour tissue; high-WNT2+: ≥37 WNT2+FGFR2+ CAFs in 1 mm³ tumour tissue. (D, E) The ratios of Tregs/CD4+ T cells (D) or IFN-γ+ CD8+ T cells/CD8+ T cells (E) between low-WNT2+ and high-WNT2+ cases were compared. The values are shown as means±SEM. **p<0.01, ****p<0.0001, using the Student’s t-test.
Figure 2. Anti-WNT2 therapy induced tumour-killing immunity and enhanced the therapeutic efficacy of anti-programmed cell death protein 1 (PD-1) in mouse oesophageal squamous cell carcinoma. (A) Schematic of the drug intervention protocol for α-WNT2 (intraperitoneally) and/or α-PD-1 (intraperitoneally) in C57BL/6 mice subcutaneously implanted with mEC25 cells. At the drug intervention end-point, mouse tissues were obtained for flow cytometry. (B) Average tumour growth curves of syngeneic mEC25 tumours in mice treated as described in (A). (C) The visual maps of mEC25 tumours by indicated treatment. The tumours were removed from mice at day 30 after mEC25 cell injection. (D) Flow cytometry was used to quantify the percentage of effective CD8+ T cells interferon (IFN)-γ in anti-WNT2, anti-PD-1 and IgG isotype-treated mice (n=5/group). (E) A cytotoxic lymphocyte assay evaluated the tumour-killing activity of CD8+ T cells isolated from mice spleens treated in (D). (F–I) Flow cytometry analysis was used to quantify the percentage of CD11c+ dendritic cells (DCs) (F), CD103+ DCs (G), CD80+CD11c+ DCs (H) and CD86+CD11c+ cells (I) in tumours from mice treated in (D). Data are shown as means±SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by two-way analysis of variance (ANOVA) in (B) or Student’s t-test in (D–I).
figure 6A,B) and the generation of their matured population (online supplemental figure 6C,D) while anti-WNT2 IgG or anti-WNT2 Fab significantly attenuated all immunosuppressive effects induced by the hWnt2 protein in vitro (online supplemental figure 6).

We next explored whether WNT2 mediates the regulation by CAFs of DC differentiation and function. Mouse FGFR2+ CAFs (mCAFs) were isolated from primary mouse OSCC tumours which were established as previously. WNT2 was primarily expressed and secreted by CAFs rather than tumour cells in mouse OSCC tumours (online supplemental figure 7A,B). The CM of mCAFs (mCAF.CM) was used to treat DC precursors, and the differentiation and immune-stimulating activity was measured. Similar to the mWnt2 protein treatment, mCAFs showed good activity for suppressing DC differentiation (figure 3A), enhancing CD11c+ DC inhibitory phenotypes (figure 3B,C), and inhibiting DC maturation (figure 3D,E), activation (figure 3F) and priming CD8+ T cells (figure 3G). Treating mCAF.CM with anti-WNT2 could significantly overcome all the immunosuppressive effects induced by mCAF.CM (figure 3), suggesting that WNT2 secretion is a critical mediator for the regulation of DC differentiation and function by CAFs.

Additionally, mCAFs were transfected with a lentivirus plasmid expressing control shRNA or Wnt2-targeting shRNA to construct mCAF-shNTC and mCAF-shWnt2, respectively (figure 4A,B). The mCAF-shNTC.CM showed similar activity to mCAF.CM, suppressing DC differentiation (figure 4C,D), activation (figure 4E) and maturation (figure 4F,G). The reduction in Wnt2 induced by specific shRNA significantly restored the differentiation and immune-stimulating activity of DCs (figure 4), showing a consistent trend with anti-WNT2 treatment. Taken together, either recombinant mWnt2/hWnt2 protein or mCAF.CM suppressed DC differentiation and function. Blocking WNT2 activities with anti-WNT2 or interfering Wnt2 expression in CAFs with Wnt2-targeting shRNA could overcome these suppressions, indicating that CAF-secreted WNT2 may play a critical role in regulating DC differentiation and function.

Knockdown of Wnt2 in mCAFs inhibits mEC25 tumour growth by enhancing the DC-mediated antitumour T-cell response.

We further explored the role of CAFs-secreted WNT2 in regulating DC-mediated antitumour immunity within the TME of solid tumours in animal model. Importantly, in a syngeneic mouse tumour model established by subcutaneous injection of mEC25 cells and mCAFs (ratio: 3:1), the reduction in Wnt2 expression in mCAFs significantly attenuated their activity in promoting mEC25 tumour progression (figure 5A,B) and suppressing the activity of CD8+ T cells (figure 5C). Compared with the results in the mCAF-shNTC+mEC25 group, the mCAF-shWnt2+mEC25 group had more CD8+ T cells producing IFN-γ (figure 5D) in the spleen. The ratio of CD45+ cells had not significantly changed (figure 5E), while an enhanced ratio of CD11c+ DCs (figure 5F) and CD103+ DCs (figure 5G) in CD45+ leucocytes of mEC25 tumours was detected in the mCAF-shWnt2 group compared with that in the control group. Additionally, an enhanced ratio of CD11c+ DCs (figure 5H) or CD103+ DCs (figure 5I) to CD11b+ cells and fewer inhibitory DCs (figure 5J) were induced by interfering with Wnt2 expression in mCAFs. The suppression of DC differentiation by CAF-secreted WNT2 would lead to a reduction in the number of activated DCs, which are responsible for priming CD8+ T cells. A reduction in Wnt2 expression in mCAFs restored the ratio of activated DCs with increased TNFα or IL12 expression and the ratio of mature DCs with CD80 or CD86 expression (figure 5K–N). These in vivo data suggest that CAFs-secreted WNT2 has an important role in suppressing DC-mediated antitumour T-cell responses by inhibiting DC immune-stimulating functions.

WNT2 suppresses the differentiation and immune-stimulating activities of DCs by upregulating SOCS3

We next explored the molecular pathway via which WNT2 regulates DC differentiation and activation. RNA sequencing analysis was performed in DCs subjected to four different treatment methods, including control CM, mWnt2, mCAF.CM and mCAF.CM+αWNT2 treatment. mCAF.CM treatment versus control and mCAF.CM+αWNT2 versus mCAF.CM treatment displayed common changes in 223 (10.6%) genes (online supplemental figure 8A). Gene ontology functional annotation analysis further showed that these common differentially expressed genes were associated with immune signalling pathways, including the TNF, JAK-STAT and NF-kB signalling pathways (online supplemental figure 8B). Of the 223 common genes, suppressor of cytokine signalling 3 (Socs3) was identified as one of the most significantly upregulated genes in both mWnt2-treated and mCAF CM-treated DCs (figure 6A). Socs3 is involved in the regulation of DC differentiation and functions. The upregulation of Socs3 induced by mCAF.CM or mWnt2 in DCs was confirmed by both qPCR (figure 6B) and western blotting (figure 6C). Anti-WNT2 treatment blocked the upregulation of Socs3 induced by mCAF.CM or mWnt2 in DCs (figure 6B,C). Socs3 is an endogenous inhibitor of JAK-STAT signalling, which is critical for GM-CSF-mediated CD103+ DC differentiation. Thus, the inhibition of JAK-STAT signalling could be a downstream target of WNT2-induced Socs3 for the regulation of DC differentiation and function. The phosphorylation of JAK2 and STAT3 (Tyr 705) was inhibited by the mWnt2 protein, while anti-WNT2 treatment abolished this inhibition (figure 6C). Importantly, the reduction in Socs3 (figure 6D) in DC precursors or DCs improved their differentiation ability (figure 6E,F) and activation (figure 6G), respectively, thereby overcoming WNT2-induced suppression of DC differentiation and activation (figure 6E–G). Socs3 reduction in DC precursors also attenuated Wnt2-induced inhibition of JAK2/STAT3 phosphorylation (figure 6H), suggesting the inhibition of JAK2/STAT3 phosphorylation induced by WNT2 is mediated by the upregulation of Socs3. Moreover, inhibiting the phosphorylation of STAT3 (Tyr 705) using Napabucasin (2 μM) showed a similar effect on suppressing DC differentiation and function compared with the results using the mWnt2 protein (online supplemental figure 9). Consistent with the in vitro data, in the animal model established by subcutaneous injection of mEC25 cells and mCAFs, a reduced level of Socs3 (figure 6I) and enhanced STAT3 phosphorylation of CD45+ leucocytes (figure 6J) were detected in tumour tissue of the mCAF-shWnt2 group compared with these values in the control group. Taken together, these findings suggest WNT2 can suppress DC differentiation by upregulating Socs3 expression and inhibiting JAK2/STAT3 signalling.
Figure 3  Anti-WNT2 treatment blocked the ability of cancer-associated fibroblasts (CAFs) to suppress dendritic cell (DC) differentiation. (A–C) Flow cytometry was used to quantify the percentage of CD11c+ cells (A), the ratios of inhibitory IDO+CD11c+ DCs (B) and IL10+CD11c+ DCs (C) in mCAF. CM-treated, mCAF.CM+IgG-treated or mCAF.CM+α-WNT2-treated C57BL/6 bone marrow cells when they were induced to DCs with interleukin (IL)-4+granulocyte/macrophage colony-stimulating factor (GM-CSF). Control: RPMI 1640 medium containing 10% FBS with GM-CSF (10 ng/mL)+IL-4 (10 ng/mL); mCAF.CM: culture medium (CM) of CAFs from primary mouse OSCC tumours mixed with control medium (ratio: 1:1). (D–F) Flow cytometry was used to quantify the ratio of CD80+CD11c+ cells (D), CD86+CD11c+ cells (E) and the percentage of TNFα+CD11c+ cells (F) to examine the stimulating activity of DCs. (G) Flow cytometry was used to evaluate the percentage of interferon (IFN)-γ+ CD8+ T cells after coincubation with mEC25 cell lysate-stimulated DCs for 5 days. For the flow cytometry analyses (A–G), the acquired events were gated based on the strategy shown in online supplemental figure 4. In (B) and (C), CD11c+ cells were further gated based on the SSC-A and CD11c-FITC plots, and analysed for percentage of IDO+CD11c+ DCs (B) and IL10+CD11c+ DCs (C). Data are shown as means±SEM. **p<0.01, ***p<0.001, ****p<0.0001, using the Student’s t-test.
Figure 4  Wnt2 interference in mCAFs attenuated its inhibition of dendritic cell (DC) differentiation in vitro. (A) Relative expression levels of Wnt2 in mCAF-shNTC or mCAF-shWnt2 were detected using qPCR (left) and western blotting (right). GAPDH was used as an internal control. (B) Wnt2 protein levels in the culture medium of mCAF-shNTC or mCAF-shWnt2 was measured by ELISA. (C and D) Flow cytometry was used to quantify the percentage of CD11c+ cells (C) or CD103+ cells (D) in the mCAF-shNTC.CM-treated or mCAF-shWnt2.CM-treated C57BL/6 bone marrow cells during their induction with interleukin 4+granulocyte/macrophage colony-stimulating factor. (E–G) Flow cytometry was used to quantify the ratios of TNFα+CD11c+ cells (E), CD80+CD11c+ cells (F) and CD86+CD11c+ cells (G) to examine the stimulating activity of DCs. For the flow cytometry analyses (C–G), the acquired events were gated based on the strategy shown in online supplemental figure 4. Data are shown as means±SEM. **p<0.01, ***p<0.001, ****p<0.0001, using the Student’s t-test.
**DISCUSSION**

Our current study revealed that CAFs-secreted WNT2 has a critical role in regulating tumour immune evasion by suppressing DC differentiation. Anti-WNT2 therapy enhanced the level of antigen-presenting DCs within tumours and thus improved the DC-mediated specific CD8+ T-cell response to tumours, leading to the suppression of tumour progression. Interestingly, anti-WNT2 therapy significantly enhanced the treatment efficacy of anti-PD-1 in syngeneic mouse tumour models. Although anti-PD-1 therapy has shown promising results in the treatment of various cancers, the objective response rate of anti-PD-1 therapy in these cancers remained relatively low.1 2 The blockade of other signalling pathways that directly suppress the tumour-killing functions of effective CD8+ T cells, such as inhibition of the CTLA-4 pathway, has been used to improve the results of treatments that use immune checkpoint inhibition.3 However, the low level of effective CD8+ T cells in tumours negatively affects the efficacy of these therapies.4 Effective synergy for killing tumour cells could be gained by enhancing the level of intratumoural effective CD8+ T cells and blocking immune checkpoints that negatively regulate the activation of effector T cells. In addition to enhancing the infiltration of CD8+ T cells into tumours, promoting the generation of effective cytotoxic T lymphocytes could be an alternative way to increase intratumoural effective CD8+ T cells. Based on our findings, combined therapy using both anti-WNT2 and anti-PD-1 antibodies has the advantage of simultaneously rescuing the initiation of tumour-specific effective CD8+ T cells and activating these
GI cancer

Figure 6  WNT2 regulates dendritic cell (DC) differentiation by upregulating SOCS3 expression. (A) A heatmap of nine genes which were commonly upregulated in mWnt2-treated and mCAF.CM-treated DCs compared with their expression in control culture medium (CM)-treated DCs, and downregulated in mCAF.CM+αWNT2-treated DCs compared with their expression in mCAF.CM-treated DCs. (B) The relative expression levels of SOCS3 in control CM-treated, mCAF.CM-treated, mCAF.CM+IgG-treated and mCAF.CM+αWNT2-treated DCs were detected by qPCR. (C) SOCS3 protein expression and the activation of JAK2/STAT3 signalling in control CM-treated, mWnt2-treated, mWnt2+IgG-treated and mWnt2+αWNT2-treated DCs were assessed by western blotting. (D) The relative expression level of SOCS3 was detected by qPCR with or without mWnt2 (100 ng/mL) treatment in si-SOCS3 or si-Control (Ctrl) transduced DC precursors during DC induction. (E–G) Flow cytometry was used to evaluate the percentage of CD11c+ cells (E) or CD103+ cells (F) and the ratio of TNFα+CD11c+ cells (G) in DCs treated as described in (D). (H) Western blotting showed JAK2/STAT3 activation in DC precursors treated as described in (D). (I, J) Flow cytometry was used to evaluate the ratios of SOCS3+CD45+ cells (I) and p-STAT3+CD45+ cells (J) in lymphocytes isolated from mouse tumour tissues as described in figure 5. Data are shown as means±SEM. *p<0.05, **p<0.01, ***p<0.001, using the Student’s t-test.

effector T cells, both of which are inhibited by TME-derived factors (figure 7).

WNT2 is highly expressed in various cancers, including oesophageal cancer, colon cancer and GC. Therefore, anti-WNT2 therapy could be used alone or in combination with other immuno-therapeutic approaches to treat these GI cancers, by enhancing the antitumour immune response. It is worth noting that WNT2 is generally absent in healthy human tissues, except the placenta and endometrium. No obvious toxicity was induced in mice by anti-WNT2 treatment in our study, suggesting WNT2-targeted therapy would be safe for cancer treatment. Pan-inhibitors of the Wnt/β-catenin pathway have been used to treat different cancers in several clinical trials. However, some members of the WNT family and their downstream effectors are essential for the normal functioning of vital organs, and may not therefore represent a good therapeutic target for cancer treatment. For example, WNT5A is highly expressed in the lungs and plays an important role in regulating their biological function. Therefore, a specific anti-WNT2 antibody may be safer and more effective than pan-inhibitors of the Wnt/β-catenin pathway in the treatment of GI tumours with WNT2 overexpression.

Due to the lack of mouse OSCC cell line, studies for CAFs-regulated antitumour immunity in OSCC is scanty. Taking advantage of a mouse OSCC cell line mEC25 generated in our group, we are able to reveal a novel mechanism in which CAFs regulate the antitumour immunity in OSCC. CAFs from oesophageal and colon cancers can use their secreted WNT2 to suppress antitumour immune responses. Depletion of WNT2-secreting CAFs would therefore improve the antitumour immune response in the TME and suppress tumour progression. It has been suggested that
CAL depleting may attenuate the generation of matrix and impair the tumour barrier, thus enhancing the infiltration of antitumour drugs. Therefore, employing a strategy of depleting WNT2-secreting CAFs in combination with PD-1 antibodies could not only work to improve antitumour immune responses but also enhance the infiltration of PD-1 antibodies into tumours. In oesophageal cancer, WNT2 is mainly secreted by FGFR2+ CAFs. However, FGFR2 is also highly expressed in healthy tissues, including the brain, skin, and bone marrow. Therefore, the identification of more specific surface markers of WNT2-secreting CAFs will be required to develop novel CAF-depletion strategies that can be used to improve the efficiency of anti-PD-1 therapy in OC (oesophageal cancer) and CRC.

DC differentiation is suppressed by tumour-derived or TME-derived factors, such as fibrinogen-like protein 2, which is highly expressed in glioma stem cells, and this suppression of DC differentiation plays a critical role in promoting tumour progression. Our data suggested CAF-derived WNT2 inhibited the differentiation of CD11c+ DCs and CD103+ DCs in tumours and thus attenuated the level of tumour-antigen presentation and CD8+ T-cell priming, without affecting the intratumoural infiltration of CD45+ cells. The activation of JAK2/STAT signalling is important for maintaining the differentiation of CD103+ DCs. Our results confirmed that the p-JAK2/p-STAT3 (Tyr705) pathway plays an essential role in maintaining the differentiation of DCs. WNT2 inhibited the activation of JAK2/STAT3 through the upregulation of SOCS3 in DC precursors. Previous studies have shown that SOCS3 is critical for regulating the function of immune cells, but it remains unclear whether SOCS3 is involved in the regulation of tumour immune-evasion. In the present study, we provide the first evidence that the expression of SOCS3 in DC precursors mediates the regulation of DC differentiation in tumours, indicating it may serve as a novel target for cancer therapy. In the future, however, it will be critical to develop an appropriate therapeutic strategy by targeting DC-derived SOCS3. Different studies have produced contradictory results with regard to the role played by JAK2/STAT signalling in the regulation of immune-cell functions. While some studies have shown that activation of the JAK2/STAT pathway is required for the differentiation of DCs and thus the maintenance of the DC-mediated T-cell response, others have shown that tumour-derived factors can impair the antitumour activities of DCs by activating JAK2/STAT signalling. This inconsistency might reflect the different roles played by JAK2/STAT signalling in regulating antitumour immune responses within different TMEs.

Taken together, our findings revealed a novel mechanism in which CAFs-secreted WNT2 regulates immune-evasion processes of tumour cells and showed that anti-WNT2 therapy could effectively improve the treatment efficacy of anti-PD-1. These findings may open a new window on our understanding of the role played by CAFs in regulating antitumour immunity and provide new directions for developing more efficient immunotherapy strategies for GI cancers.

Correction notice This article has been corrected since it published Online First. The first author statement has been added.

Contributors T-XH, X-YT and H-SH acquired the animal data. T-XH, X-YT, H-SH and Y-TL performed the in vitro cell experiments. B-LL, ZC and XYG acquired the patient-tissue IHC data. K-SL, XC and CZ acquired the antibody binding data. T-XH and LF designed the study, analysed the data and wrote the manuscript. LF supervised the study and revised the manuscript.

Funding This work was supported by grants from the National Key R&D Programme of China (2017YFA0503900), the National Natural Science Foundation of China (81772583 and 81772957), the Science and Technology Programme of Guangdong Province in China (2018B030301009), the Industry and Information Technology Foundation of Shenzhen (2018030901033580), the Shenzhen Basic Research Programme (JCYJ20200109113810154), the SZU Top Ranking Project (86000000210) and the RGC CRF Project (C7065-18G).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplementary material.
supplementary information. Data are available in public, open access repositories, directly included in the article, uploaded as supplementary information from first or last authors. RNA-seq data are publicly available through the NIH GEO platform (https://www.ncbi.nlm.nih.gov/geo/); GEO accession no. GSE154420.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMI Publishing Group Limited (BMD) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMI. BMI disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMI does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID ID**

Li Fu [http://orcid.org/0000-0003-2643-6278](http://orcid.org/0000-0003-2643-6278)

**REFERENCES**

1. Tang J, Yu JX, Hubbard-Lucey VM, et al. Trial watch: the clinical trial landscape for PD-1/PDL1 immune checkpoint inhibitors. *Nat Rev Drug Discov* 2018;17:854–5.
2. Zhao P, Li L, Jiang X, et al. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. *J Hematol Oncol* 2019;12:54.
3. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. *J Clin Invest* 2015;125:3384–91.
4. Baumeister SH, Freeman GI, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. *Ann Rev Immunol* 2016;34:539–73.
5. Rabonovich GA, Gabilovich D, Sotomayer EM. Immunosuppressive strategies that are mediated by tumor cells. *Ann Rev Immunol* 2007;25:267–96.
6. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* 2005;121:33–48.
7. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. *Science* 2010;330:827–30.
8. Wen Y, Wang C-T, Ma T-T, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. *Cancer Sci* 2010;101:2325–32.
9. Huang TX, Fu L. The immune landscape of esophageal cancer. *Cancer Commun* 2019;39:79.
10. Zhang C, Fu L, Fu J, et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. *Clin Cancer Res* 2009;15:4017–27.
11. Fu L, Zhang C, Zhang L-T, et al. Wnt2-secreting tumour fibroblasts promote tumour progression in oesophageal cancer by activation of the Wnt/beta-catenin signalling pathway. *Gut* 2011;60:1635–43.
12. Logan CY, Nussle R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol* 2004;20:781–810.
13. Kramer N, Schmülling T, Unger C, et al. Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. *Oncogene* 2017;36:5460–72.
14. Zhang Q, Wang J, Dong X. Wnt2 contributes to the progression of gastric cancer by promoting cell migration and invasion. *Oncol Lett* 2018;16:2857–64.
15. Xi H-D, Liu G-F, Yu S-N, et al. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/beta-catenin signaling pathway by regulating WNT2. *J Exp Clin Cancer Res* 2019;38:94.
16. Dale TC, Weber-Hall SJ, Smith K, et al. Compartment switching of WNT-2 expression in human breast tumors. *Cancer Res* 1996;56:4320–3.
17. Katch O, WNT2 and human gastrointestinal cancer (review). *Int J Mol Med* 2003;12:811–6.
18. Staal FJ, Lu S, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. *Nat Rev Immunol* 2008;8:581–93.
19. Xiao J, Zhou H, Wu N, et al. The non-canonical Wnt pathway negatively regulates dendritic cell differentiation by inhibiting the expansion of FoxP3(+)-lymphocyte-pimmed multipotent precursors. *Cell Mol Immunol* 2016;13:593–604.
20. Zhou J, Cheng P, Youn J-L, et al. Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. *Immunity* 2009;30:845–59.
21. Wang B, Tian T, Kalland K-H, et al. Targeting Wnt/b-catenin signalling for cancer immunotherapy. *Trends Pharmacol Sci* 2018;39:648–58.
22. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. *Nature* 2015;523:231–5.
23. Zhao F, Xiao C, Evans KS, et al. Paracrine Wnt5a-B-catenin signaling triggers a metabolic program that drives dendritic cell Tolerization. *Immunity* 2018;48:147–60.
24. Huang T, Perez-Cordon G, Shi L, et al. Clostridium difficile toxin B intoxicated mouse colonic epithelial CT26 cells stimulate the activation of dendritic cells. *Pathog Dis* 2015;73:ftv008.
25. Gardner A, Ruffell B. Dendritic cells and cancer immunity. *Trends Immunol* 2016;37:85–65.
26. Huang T, Yang J, Liu B, et al. A new mouse esophageal cancer cell line (mEC25)-derived pre-clinical syngeneic tumor model for immunotherapy. *Cancer Commun* 2020;40:316–20.
27. Li Y, Chu N, Rostami A, et al. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic DC/C2 phenotype that directs type 2 cell differentiation in vitro and in vivo. *J Immunol* 2006;177:1679–88.
28. Li Y, de Haar C, Peppelendorf MP, et al. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. *Cytokine Growth Factor Rev* 2012;23:127–38.
29. Yan J, Zhao Q, Gabusiewicz K, et al. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. *Nat Commun* 2019;10:448.
30. Teng MWL, Ngiov SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-1. *Cancer Res* 2015;75:2139–45.
31. Ferreira JC, Choufani S, Grafodatskaya D, et al. WNT2 promoter methylation in human placenta is associated with low birthweight percentile in the neonate. *Epidemiogen* 2011;6:640–9.
32. Bui TD, Zhang L, Rees MC, et al. Expression and hormone regulation of WNT2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. *Br J Cancer* 1997;75:1131–6.
33. Krishnamurthy A, Dasari A, Noonan AM, et al. Phase Ib results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer. *Cancer Res* 2018;78:5398–407.
34. Ahmed K, Shaw HV, Koval A, et al. A second Wnt for old drugs: drug repositioning against WNT-Dependent cancers. *Cancers* 2018;6:86.
35. Li C, Hu L, Xiao J, et al. Wnt5a regulates Shh and Fgf10 signaling during lung development. *Dev Biol* 2005;287:86–97.
36. Li C, Xiao J, Horm K, et al. Wnt5a participates in distal lung morphogenesis. *Dev Biol* 2002;248:68–81.
37. Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. *J Clin Invest* 2006;116:1955–62.
38. Finch M, Bonomo A, Trovato-Salinaro A, et al. Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. *Neurosci Lett* 2008;447:20–5.
39. Caya M. Fibroblast growth factor receptor signaling in skin cancers. *Cells* 2019;8:540.
40. Shigematsu A, Shi M, Okigaki M, et al. Signaling from fibroblast growth factor receptor 2 in immature hematopoietic cells facilitates donor hematopoiesis after intra-bone marrow-bone marrow transplantation. *Stem Cells Dev* 2010;19:1679–86.
41. Zhong J, Yang P, Muta K, et al. Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. *PLoS One* 2010;5:e10993.
42. Melillo JA, Song L, Bhagat G, et al. Dendritic cell (DC)-specific targeting reveals Stats3 as a negative regulator of DC function. *J Immunol* 2010;184:2638–45.
43. Alshamsan A, Hamdy S, Das S, et al. Validation of bone marrow-derived dendritic cells as a unique model to study tumor-metastasized DC maturation through STAT3 hyperactivation. *J Pharm Pharm Sci* 2010;13:21–6.